Zhaoming Li

7PUBLICATIONS
5CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursNeurogeneticsMedical genetics (excl. cancer genetics)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 18, 2020
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.

Lijun Du, Lei Zhang, Ling Li

|Mar 12, 2020
Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.

Xinran Ma, Ling Li, Lei Zhang

|Oct 02, 2019
Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China.

Xiangli Liu, YuFeng Shang, Ling Li

|Sep 19, 2019
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.

Zhaoming Li, Xudong Zhang, Weili Xue

|Mar 31, 2019
The clinical features and prognosis of 100 AIDS-related lymphoma cases.

Dedong Wu, Chen Chen, Mingzhi Zhang

|Jun 10, 2017
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.

Ling Li, Wenjing Duan, Lei Zhang

Pageof 2

Frequent Collaborators

2 joint publications

Mingzhi Zhang

1 joint publications

Wenjing Duan

1 joint publications

Xinran Ma

1 joint publications

Lijun Du